Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward

Shankar, Abhishek; Saini, Deepak; Dubey, Anusha; Roy, S. C. Dutta; Bharati, Sachidanand Jee; Singh, Navneet; Khanna, M.; Prasad, Chandra Prakash; Singh, Mayank; Kumar, Sunil; Sirohi, Bhawna; Seth, Tulika; Minakshi, Rinki; Mohan, Anant; Guleria, Randeep; Rath, Goura Kishor

doi:10.21037/tlcr.2019.03.03

Cited by 65 publications

(43 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2018, over two million new lung cancer (LC) cases were diagnosed, and over 1.3 million people have died from LC, making this disease the most common occurring malignant disease in the world, as well as the most common cause of cancer-related deaths [59]. Although LC is a model cancer for the success of molecular targeted therapies [105,106], due to the high cost of radiologically-based nation-wide screening programs [107,108], it is most often diagnosed in advanced disease stages when the level of cancer-related pain is high [109]. An individual combination of pharmacological and non-pharmacological approaches for each patient ensures the optimal palliative care which results in higher quality of life and longer survival.…”

Section: Thoracic Tumoursmentioning

confidence: 99%

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

Moreno

Čavić

Krivokuća

et al. 2020

Cancers

View full text Add to dashboard Cite

The various components of the endocannabinoid system (ECS), such as the cannabinoid receptors (CBRs), cannabinoid ligands, and the signalling network behind it, are implicated in several tumour-related states, both as favourable and unfavourable factors. This review analyses the ECS’s complex involvement in the susceptibility to cancer, prognosis, and response to treatment, focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, CNS tumours, and melanoma). Changes in the expression and activation of CBRs, as well as their ability to form distinct functional heteromers affect the cell’s tumourigenic potential and their signalling properties, leading to pharmacologically different outcomes. Thus, the same ECS component can exert both protective and pathogenic effects in different tumour subtypes, which are often pathologically driven by different biological factors. The use of endogenous and exogenous cannabinoids as anti-cancer agents, and the range of effects they might induce (cell death, regulation of angiogenesis, and invasion or anticancer immunity), depend in great deal on the tumour type and the specific ECS component that they target. Although an attractive target, the use of ECS components in anti-cancer treatment is still interlinked with many legal and ethical issues that need to be considered.

show abstract

Section: Thoracic Tumoursmentioning

confidence: 99%

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

Moreno

Čavić

Krivokuća

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Low dose computed tomography has been recommended for lung cancer screening, as this is proven to be an effective modality with mortality reduction benefit. Most countries or organizations have not framed any guidelines for lung cancer screening due to cost-effectiveness and morbidity issues related to low dose computed tomography [11]. In this current situation, all organizations/institutions have recommended to postpone routine lung cancer screening for high risk smokers.…”

Section: Challenges In Lung Cancer Screeningmentioning

confidence: 99%

Lung Cancer Management Challenges Amidst COVID-19 Pandemic: Hope Lives Here

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…Uptake of LDCT in high-income countries with the resources to implement population-based lung cancer screening is low (Li et al, 2018;Rai et al, 2019). In low and middle income countries challenged with establishing the necessary infrastructure to support LDCT lung cancer screening, training healthcare personnel, and developing referral algorithms, LDCT screening is practically non-existent (Pinsky, 2018;Raez et al, 2018;Shankar et al, 2019). Instead, tobacco control and prevention strategies used in smoking cessation programmes will likely be the most important interventions for decreasing lung cancer morbidity and mortality in developing countries at this time (Raez et al, 2018;Shankar et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Attitudes toward tobacco cessation and lung cancer screening in two South African communities

Hillyer

Mapanga

Jacobson

et al. 2020

Global Public Health

View full text Add to dashboard Cite

Among men in South Africa, the prevalence of tobacco smoking is as high as 33%. Although smoking is responsible for most lung cancer in South Africa, occupational and environmental exposures contribute greatly to risk. We conducted a tobacco and lung cancer screening needs assessment and administered surveys to adults who smoked >100 cigarettes in their lifetime in Johannesburg (urban) and Kimberley (rural). We compared tobacco use, risk exposure, attitudes toward and knowledge of, and receptivity to cessation and screening, by site. Of 324 smokers, nearly 85% of current smokers had a <30 pack-year history of smoking; 58.7% had tried to stop smoking ≥1 time, and 78.9% wanted to quit. Kimberley smokers more often reported being advised by a healthcare provider to stop smoking (56.5% vs. 37.3%, p=0.001) than smokers in Johannesburg but smokers in Johannesburg were more willing to stop smoking if advised by their doctor (72.9% vs. 41.7%, p<0.001). Findings indicate that tobacco smokers in two geographic areas of South Africa are motivated to stop smoking but receive no healthcare support to do so. Developing high risk criteria for lung cancer screening and creating tobacco cessation infrastructure may reduce tobacco use and decrease lung cancer mortality in South Africa.

show abstract

Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward

Cited by 65 publications

References 118 publications

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

Lung Cancer Management Challenges Amidst COVID-19 Pandemic: Hope Lives Here

Attitudes toward tobacco cessation and lung cancer screening in two South African communities

Contact Info

Product

Resources

About